Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies


  • Indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Fedratinib (Inrebic) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis and exhibits comparable efficacy to other Janus kinase inhibitors such as momelotinib and ruxolitinib in reducing spleen volume and alleviating total symptom scores.
  • Two studies were reviewed, which provided information about Inrebic's comparison with other JAK inhibitors for the treatment of myelofibrosis.
  • The studies suggest that fedratinib has a distinctive advantage over some counterparts due to lesser toxicity on platelets, indicating its favorable profile for individuals concerned about thrombocytopenia.
  • When considering first-line therapy, fedratinib, along with momelotinib and ruxolitinib, are viable options; however, there may be potential benefits of selecting fedratinib or momelotinib for individuals at risk of anemia and thrombocytopenia, respectively.
  • As part of second-line therapy considerations, pacritinib appears less effective than ruxolitinib but shows promise post-ruxolitinib exposure, while fedratinib remains a critical option across the spectrum.
  • Fedratinib also falls under JAK inhibitors, which have been associated with a significantly reduced risk of mortality among hospitalized COVID-19 patients, although further details would be required to understand its specific contribution within this context.

Product Monograph / Prescribing Information

Document TitleYearSource
Inrebic (fedratinib) Prescribing Information.2023Bristol-Myers Squibb, New York, NY

Systematic Reviews / Meta-Analyses